do glp 1 reduce cancer risk Both GLP-1 Receptor Agonists and Bariatric Surgery Lower the of Weight-Related in Patients With Obesity GLP-1 use linked to lower

Historically, obesity was stigmatized and under-treated, often perceived as a result of poor lifestyle choices rather than as a complex metabolic condition

It now includes oral GLP-1 drugs, amylin combinations, dual agonists, triple agonists, long-acting platforms, and differentiated assets designed for durability, tolerability, access, or broader metabolic indications

The National Institute for Health and Care Excellence (NICE) guideline NG28 recognises both drug classes as treatment options within the type 2 diabetes management pathway

Modrzejewska-Sikorska A, Robakowska M, Konowa E, Gojzewski H, Gierz , Wieczorek B et al (2023) Lignin and starch derivatives with selenium nanoparticles for the efficient reduction of dyes and as polymer fillers